Objectives. To validate the ACR-EULAR classification criteria for primary SS (pSS), and compare them to the AmericanEuropean Consensus Group (AECG) and ACR criteria in a Dutch prospective diagnostic cohort.
Introduction
Primary SS (pSS) is a systemic autoimmune disease, characterized by lymphocytic infiltration of the exocrine glands, resulting in dryness symptoms [1] . Patients present with a spectrum of signs and symptoms, evolving over time, making clinical diagnosis and classification challenging.
Currently, multiple criteria sets are in use for classification of pSS (supplementary Table S1 , available at Rheumatology online). Most researchers and clinicians utilize the 2002 AmericanEuropean Consensus Group (AECG) criteria, which include items evaluating the presence of sicca symptoms of the eye and mouth, functional impairment of the exocrine glands, presence of anti-SSA/ SSB antibodies and a focus score of 51 in the salivary gland biopsy [2] . However, questions were raised about the inclusion of sicca symptoms in the AECG criteria. Therefore, in 2012, Shiboski et al. proposed the ACR criteria for pSS. The ACR criteria include only objective tests and were designed to be used as entry criteria for clinical trials, in order to ease comparison of results between trials [3] . The ACR criteria require the presence of two out of the following three items: focus score of 51, positive serology and ocular staining score (OSS) 53. Positive serology was defined as the presence of anti-SSA/SSB antibodies or RF and ANA. Agreement between the AECG and ACR criteria was 78 and 81% in two prospective diagnostic cohorts [4, 5] .
Although widely used, the AECG and ACR criteria sets have not been endorsed by both the ACR and the EULAR. To be able to compare different study populations in trials and cohorts, international consensus regarding the classification of pSS is crucial. Therefore, the International Sjö gren's Syndrome Criteria Working Group developed the 2016 ACR-EULAR criteria for pSS using methodology endorsed by both the ACR and EULAR [6, 7] .
The ACR-EULAR criteria combine features of the AECG and ACR criteria (supplementary Table S1 , available at Rheumatology online). Instead of including sicca symptoms as an item, the ACR-EULAR criteria added the presence of sicca symptoms or a EULAR Sjö gren's syndrome disease activity index (ESSDAI) of 51 as an entry criterion. In the ACR-EULAR criteria, positive serology is solely based on the presence of anti-SSA antibodies, while anti-SSB, ANA and RF positivity were not adopted. The OSS score was added to the ACR-EULAR criteria with a cut-off of 55, instead of 53 as used for the ACR criteria, and the van Bijsterveld score with a cut-off of 54 was allowed as an alternative. Sialography and scintigraphy were not included in the ACR-EULAR criteria and some updates were made in the exclusion criteria for classification as pSS.
Before the ACR-EULAR classification criteria can be implemented reliably, it is important to validate these criteria in external, prospective cohorts with complete data on all ACR-EULAR items. Recently, the ACR-EULAR criteria were validated in a cohort of Japanese patients [8] . However, this study had several limitations. The analysis was performed in a retrospective cohort with incomplete data. In some of the patients, unstimulated whole saliva (UWS) was replaced by tests assessing stimulated whole saliva. OSS was not available, and replaced by the van Bijsterveld score, making the comparison with the ACR criteria less reliable. Moreover, clinical diagnosis was used as the gold standard instead of expert classification based on anonymized case vignettes. Considering these limitations, and taking into account that the Japanese population may not show the same characteristics as Caucasian populations, further validation of the ACR-EULAR criteria is needed.
The primary objective of our study is therefore to validate the ACR-EULAR criteria for pSS using classification according to expert opinion as the gold standard, in a Dutch prospective diagnostic cohort in a daily clinical practice setting. In addition, the performance of the individual components of the ACR-EULAR criteria was assessed, and the ACR-EULAR criteria were compared with the AECG and ACR criteria.
Methods

Study population
The study population consisted of consecutive patients, aged 518 years, who were referred to the Sjö gren Expertise Centre of the University Medical Centre Groningen, a tertiary referral centre, for suspicion of pSS between December 2013 and August 2016. Informed consent was obtained from all patients according to the Declaration of Helsinki. Patients with incomplete diagnostic work-up making it impossible to apply the AECG, ACR and ACR-EULAR criteria were excluded, as well as patients who were diagnosed with an associated systemic auto-immune disease (e.g. RA, SLE), as determined by the expert panel. The study was approved by the Medical Research Ethics Committee of the University Medical Centre Groningen (METc2013.066).
Diagnostic evaluation
Patients were evaluated by a team of clinical experts, consisting of rheumatologists, oral and maxillofacial surgeons, pathologists and one ophthalmologist, all highly experienced in diagnosing pSS. The multidisciplinary work-up included evaluation of all items of the three criteria sets [2, 3, 6, 7] . The rheumatologist performed a clinical history and physical examination, and recorded the presence of signs and symptoms of pSS and the ESSDAI score [9] . Laboratory tests included evaluation of complete blood count, ESR, CRP, ANA, anti-SSA and anti-SSB antibodies, RF, IgG, complement C3 and C4, cryoglobulinaemia and hepatitis C serology. When indicated, additional examinations such as X-rays, pulmonary function tests, thoracic high resolution CT or nailfold capillaroscopy were performed to facilitate clinical diagnosis.
Evaluation by the oral and maxillofacial surgeon included determination of sicca symptoms, a physical evaluation of the oro-facial and neck area and analysis of UWS and stimulated whole saliva. A labial and/or parotid gland biopsy was taken by the same oral and maxillofacial surgeon [10] . Salivary gland sialography or scintigraphy was not performed. Salivary gland biopsies were evaluated by a head and neck pathologist and trained resident for focus score (foci/4 mm 2 ) [11] , presence of germinal centres, lymphoepithelial lesions and IgA, IgG and IgM plasma cell ratio. Ophthalmological evaluation included determination of sicca symptoms, Schirmer's test, tear break-up time and OSS. OSS was defined using slit-lamp evaluation of lissamine green staining of the temporal and medial conjunctiva and fluorescein staining of the cornea [12] .
Case ascertainment
All patients were classified as pSS or non-pSS according to the ACR-EULAR, AECG and ACR criteria [2, 3, 6, 7] . Fulfilment of the classification criteria was determined separately using the labial or parotid gland biopsy outcome for classification. Patients who did not undergo both biopsies, making it impossible to determine classification when either the labial or parotid gland biopsy results were taken into account, were excluded from that part of the analysis. Although the AECG criteria exclude patients with lymphoma, we classified patients with mucosa-associated lymphoid tissue (MALT) lymphoma who fulfilled the AECG criteria as pSS, as pSS can result in the development of MALT lymphoma [13] .
The clinical diagnosis made by the treating rheumatologist was recorded. For expert classification, all cases were described in an anonymized clinical vignette, including the outcomes of all tests described above, which were reviewed by an expert panel (H.B., A.J.S., E.B.) and scored as pSS or non-primary SS (non-pSS). H.B. reviewed all vignettes, while A.J.S. and E.B. each reviewed half of the vignettes. The experts were blinded to the clinical diagnosis and classification by the other experts. In cases of discordance between the classifications by the experts, the vignette was discussed in a consensus meeting with all three experts to reach expert classification.
Statistical analysis
Statistical analyses were executed using SPSS Statistics 23 (IBM Corp., Armonk, NY, USA). Descriptive sociodemographic and disease characteristics were described as mean (S.D.), median (interquartile range) or number (%) as appropriate. The agreement between the clinical diagnosis and expert classification and between the three criteria sets was evaluated with percentage of absolute agreement and Cohen's k coefficient. The performance of the ACR-EULAR score and individual ACR-EULAR items to predict expert classification was evaluated with the area under the ROC curve (AUC), which was interpreted as no discrimination (00.5), poor (0.50.7), fair (0.70.8), good (0.80.9) or excellent (0.91.0) accuracy [14] . The agreement of the three criteria sets with expert classification was evaluated with the percentage of absolute agreement, Cohen's k coefficient, sensitivity and specificity. k was interpreted as poor (0.00.2), fair (0.20.4), moderate (0.40.6), good (0.60.8) or excellent (0.81.0) agreement [15] .
Results
Of the 129 consecutive patients who gave informed consent, 15 were excluded from evaluation in this study because of incomplete data or associated auto-immune diseases (Fig. 1) . All remaining patients (n = 114) underwent a salivary gland biopsy. For most patients (n = 100), biopsies of both glands were obtained, but five patients underwent only a labial gland biopsy and nine patients underwent only a parotid gland biopsy. 
Expert classification
After the first evaluation of the case vignettes, the expert panel agreed on the classification as pSS or non-pSS in 104 patients. For the remaining 10 patients, expert classification was reached during the consensus meeting. Of the 34 patients classified as pSS by the expert panel, the mean age was 52.3 (S.D. 15.3) years and 32 (94%) patients were female. Of the 80 patients classified as non-pSS, the mean age was 50.2 (S.D. 12.6) years and 69 (86%) patients were female.
The expert classification showed 89% agreement with the clinical diagnosis made by the treating rheumatologist (k = 0.77). Eleven patients were clinically diagnosed with pSS by the treating physician, but classified as non-pSS by the experts, and one patient was clinically not diagnosed with pSS, but classified as pSS by the experts.
Comparison of criteria with expert classification
Taking the labial gland biopsies into account for classification, the ACR-EULAR score had an AUC of 0.94 (95% CI: 0.88, 1.00) to discriminate pSS from non-pSS. The ACR-EULAR criteria and AECG criteria both showed an absolute agreement of 87% (k = 0.73) with expert classification, with 97% sensitivity and 83% specificity ( Table 1 ). The ACR criteria showed an absolute agreement of 91% (k = 0.79) with expert classification, with 91% sensitivity and 91% specificity.
Taking the parotid gland biopsies into account for classification, the ACR-EULAR score had an AUC of 0.97 (95% CI: 0.92, 1.00) to discriminate pSS from non-pSS. The ACR-EULAR criteria and AECG criteria both showed an absolute agreement of 92% (k = 0.82) with expert classification, with 91% sensitivity and 92% specificity ( Table  1 ). The ACR criteria showed an absolute agreement of 93% (k = 0.83) with expert classification, with 85% sensitivity and 96% specificity.
Description of patients with discrepant ACR-EULAR and expert classification
Characteristics of patients with concordance or discrepancy between the expert and ACR-EULAR classification are shown in Fig. 2 and Fig. 3 , taking into account the labial or parotid gland biopsy for classification, respectively. Patients who were classified as non-pSS by the experts but pSS by the ACR-EULAR criteria showed low biological activity, and most of them had ACR-EULAR scores between 4 and 6. Interestingly, the Schirmer's test was often positive, while the OSS was mostly negative in this group of patients. Patients who were classified as pSS by the experts but non-pSS by the ACR-EULAR criteria, when taking into account the labial (n = 1) or parotid gland biopsy (n = 3) for classification, were not included in the figures. However, a detailed list of discrepant cases is provided in supplementary Table S2 , available at Rheumatology online. Of these 17 discrepant cases, 9 were also classified differently by the two experts during the first round of evaluation. For these patients, expert classification was reached during the consensus meeting.
Performance of individual ACR-EULAR items
In this prospective cohort, 33 (97%) pSS patients and 78 (98%) non-pSS patients reported sicca symptoms. The ESSDAI was 51 in 31 (91%) pSS patients and 40 (51%) non-pSS patients. Only one non-pSS patient did not fulfill the entry criteria of the ACR-EULAR criteria, as she had neither sicca complaints nor an ESSDAI 5 1. None of the patients was solely SSB positive. Focus score and anti-SSA titre showed excellent accuracy and OSS showed good accuracy to discriminate pSS from non-pSS. UWS and Schirmer's test showed poor accuracy to discriminate pSS from non-pSS (Fig. 4) . 
FIG. 2 Characteristics of groups including the labial gland biopsy results
Comparison of patients who are classified as SS or non-pSS by the experts and ACR-EULAR criteria including the labial gland biopsy results. OSS: ocular staining score; UWS: unstimulated whole saliva.
FIG. 3 Characteristics of groups including the parotid gland biopsy results
Comparison of patients who are classified as SS or non-pSS by the experts and ACR-EULAR criteria including the parotid gland biopsy results. OSS: ocular staining score; UWS: unstimulated whole saliva.
Comparison of ACR-EULAR with AECG and ACR classification
Taking the labial gland biopsies into account, the ACR-EULAR criteria showed an absolute agreement of 98% (k = 0.96) with the AECG criteria and 91% (k = 0.81) with the ACR criteria ( Table 2) . Taking the parotid gland biopsies into account, the ACR-EULAR criteria showed an absolute agreement of 98% (k = 0.96) with the AECG criteria and 95% (k = 0.90) with the ACR criteria.
While ACR-EULAR classification was very similar to AECG classification, ACR classification was stricter, as some patients were classified as pSS by the ACR-EULAR criteria but as non-pSS by the ACR criteria. These patients had either a positive biopsy or positive serology, in combination with a positive UWS and/or Schirmer's test, but a negative OSS.
Discussion
This study evaluated the validity of the 2016 ACR-EULAR criteria for pSS, in comparison with the AECG and ACR criteria, in an external, prospective diagnostic cohort in a daily clinical practice setting. All ACR-EULAR items were evaluated, including labial and/or parotid gland biopsies in all patients. In our multidisciplinary setting, the ACR-EULAR score showed excellent accuracy with expert classification as the gold standard.
In accordance with the original validation cohort [6] , the ACR-EULAR criteria showed very high sensitivity when labial gland biopsies were used. We found a specificity of 83%, which is lower than the specificity of 95% reported by Shiboski et al. [7] . Recently, an even lower specificity of 76.7% was found in a retrospective cohort of Japanese patients [8] . Taken together, these results https://academic.oup.com/rheumatology suggest that some non-pSS sicca patients may be misclassified as pSS by the ACR-EULAR criteria. This occurs mostly in patients who have an ACR-EULAR score of 46, based on either presence of SSA antibodies or focus score 51, combined with a decreased Schirmer's test and/or UWS. In approximately half of the patients with discrepancy between the expert and ACR-EULAR classification, the experts also disagreed on the classification after the first round of evaluation of the vignettes. This illustrates that a subset of patients suspected for pSS is difficult to diagnose. Using the cut-off of 54 for the ACR-EULAR score does ensure high sensitivity of the ACR-EULAR criteria, but for the clinical diagnosis, other clinical parameters have to be taken into account too, including more detailed histopathological characteristics (i.e. presence of germinal centres, lymphoepithelial lesions and plasma cell shift), the presence of comorbidities that may also partly explain the symptoms (i.e. presence of diabetes, autoimmune thyroiditis, FM) and the use of medication that may cause sicca symptoms (i.e. beta blockers, antidepressants).
In our cohort, in most patients labial and parotid gland biopsies were taken simultaneously, which gave us the unique opportunity to evaluate the performance of the ACR-EULAR criteria when including labial as well as parotid gland biopsies. We found that the ACR-EULAR criteria also have excellent accuracy when using parotid gland biopsies, with good sensitivity and specificity. Interestingly, the sensitivity of the ACR-EULAR criteria is higher when using labial gland biopsies, while the specificity is higher when using parotid gland biopsies. A detailed comparison between the labial and parotid gland biopsy from a histopathological point of view falls beyond the scope of this article and will be discussed separately (Haacke EA, manuscript in preparation).
In the analysis of the performance of individual ACR-EULAR items, the salivary gland focus score, anti-SSA and OSS showed good or excellent discriminative value. The accuracy of Schirmer's test and UWS was poor as they were positive in many non-pSS patients as well. In line with our findings, Shiboski et al. [3] reported limited validity of these tests in the SICCA cohort, using a latent class model. In contrast, Vitali et al. [16] did find acceptable validity of Schirmer's test and UWS, but the study population was different. Vitali et al. included selected patients, pre-defined as patients with pSS, secondary SS or controls based on clinical judgment, whereas our cohort and the SICCA cohort included consecutive patients, resulting in a population representative of daily clinical practice.
The poor performance of Schirmer's test and UWS in our cohort might be explained by non-pSS patients with exocrine gland dysfunction due to other causes, as Schirmer's test and UWS are not able to discriminate between different causes of sicca symptoms [17, 18] . The OSS shows good performance in our cohort, and we strongly recommend including evaluation of the OSS in the diagnostic work-up of SS. However, the OSS needs to be performed by a trained ophthalmologist, which is not always available. Therefore, the inclusion of Schirmer's test and UWS in the ACR-EULAR criteria has increased the feasibility of the criteria. To further improve the ACR-EULAR criteria, additional studies should evaluate whether other diagnostic tests such as salivary gland ultrasonography could complement the ACR-EULAR criteria [19] .
As expected, the ACR-EULAR classification was very similar to the AECG classification, and showed equal validity in our cohort. However, the ACR-EULAR criteria have several advantages over the AECG criteria in current daily practice. For example, the sensitivity of the AECG criteria would have been lower if the three pSS patients with MALT lymphoma in our cohort had been characterized as non-pSS, according to the exclusion criteria (data not shown). Lymphoma is no longer included in the exclusion criteria of the ACR-EULAR, and other exclusion criteria have also been adjusted. Additionally, sialography and scintigraphy have been excluded from the ACR-EULAR criteria as they are no longer commonly used for the evaluation of pSS. Sialography is a painful, time-consuming procedure and is contraindicated in patients with severe salivary gland dysfunction. Scintigraphy exposes patients to radiation, has limited specificity and is not widely available [20] .
Compared with the ACR criteria, the ACR-EULAR criteria show slightly lower absolute agreement with expert consensus and lower specificity. On the other hand, the ACR-EULAR criteria show higher sensitivity, similar to recent findings in Japanese patients [8] . Furthermore, the ACR-EULAR criteria are more feasible than the ACR criteria in daily clinical practice, as it is often not necessary to perform a salivary gland biopsy or ocular staining score to reach the cut-off of 54 for classification as pSS. To avoid inclusion of patients who are misclassified as pSS in therapeutic trials, we do recommend performing a full diagnostic work-up [19] .
An important strength of this study is the use of expert classification as gold standard. The AECG criteria are commonly used in our hospital, as shown by an agreement of 94% between the AECG criteria and the clinical diagnosis of the treating physician (data not shown). As the ACR-EULAR and AECG criteria show high agreement, the validity of the ACR-EULAR classification would be overestimated when using clinical diagnosis by the treating physician as gold standard. Our expert panel consisted of three rheumatologists with broad experience in diagnosing pSS patients. Agreement between the treating physician and the expert panel was high, but the experts were stricter than the treating physician. A possible limitation is that the expert panel consisted only of physicians working in our expertise centre. For some of the cases, one of the evaluating experts was therefore also the treating physician of the patient. We cannot exclude the possibility that despite anonymization, some cases may have been recognized by the experts, but the influence of this potential source of bias is limited as all cases were evaluated by at least two experts. We did not include sialography and scintigraphy in our diagnostic work-up, which might have influenced our results regarding the AECG classification. However, as sialography and scintigraphy are not commonly performed any more to diagnose pSS, we believe our results are representative of how the AECG criteria are most often applied.
In conclusion, the ACR-EULAR criteria showed excellent diagnostic accuracy in our prospective cohort. The ACR-EULAR criteria also have excellent accuracy when using parotid gland biopsies, with good sensitivity and specificity. The validity of Schirmer's test and UWS, as well as addition of new items should be further evaluated. Based on our results, we strongly recommend performing OSS to evaluate ocular signs of pSS. The ACR-EULAR criteria showed validity equal to the AECG criteria, and compared with the ACR criteria, high sensitivity but lower specificity. The ACR-EULAR criteria have important advantages compared with other criteria sets, and have been endorsed by both the ACR and EULAR, allowing for international consensus regarding the classification of pSS.
